Loading news...
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
While the market fixates on short-term product cycles, Hims & Hers (HIMS) is quietly building a healthcare platform, aiming to control the primary interface for diagnostics, prevention, and personalized treatments. The introduction of "Labs" creates the data layer for continuous health optimization, deepening engagement and enabling increasingly precise, personalized care over time. Scale achieved from making healthcare accessible to millions helps the company drive down unit costs, lower prices, expand adoption, and create a self-reinforcing flywheel of growing reach, engagement, and long-term platform value.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, announced that it's heading back to the Big Game this year. On February 8th, Hims & Hers will follow up its hit “Sick of the System” ad, debuting a new national spot “Rich People Live Longer” with a simple message: the era of health as a luxury good is over, and proactive, life-changing care belongs to everyone. The campaign centers on the uncomfortable tru.
Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. HIMS's recurring revenue model, 70%+ gross margins, and rapid subscriber growth underpin a compelling long-term growth thesis despite recent profit volatility. Significant investments in global expansion, new product lines, and vertical integration are expected to drive future margin expansion and revenue acceleration.
Hims & Hers Health, Inc. (HIMS) reached $29.68 at the closing of the latest trading day, reflecting a -1.98% change compared to its last close.
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Health Inc (NYSE:HIMS) shares are up 3.4% to trade at $30.60 at last glance.
HIMS expands its tech-driven care platform with new diagnostics, AI tools and specialty treatments for personalized health.
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Profitability This table compares
Revenue grew nearly 50% year over year in Q3 2025 to ~$600 million, with ARPU rising and free cash flow reaching $79 million. Gross margin declined to ~74% from high-70s levels due to GLP-1 shipping cadence changes, price cuts, and facility expansion inefficiencies. Operating cash flow approached $150 million in the quarter, with over $1 billion in cash and investments supporting reinvestment and buybacks.
Stock News TikTok sets up U.S. data-security JV: TikTok USDS Joint Venture LLC launched as a majority American-owned entity to safeguard U.S. user data, algorit
Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right now? Let's dive in.
Emerald Advisers LLC acquired a new position in shares of Hims and Hers Health, Inc. (NYSE: HIMS) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 305,921 shares of the company's stock, valued at approximately $17,352,000. Emerald Advisers LLC owned about 0.14%
Hims and Hers Health (NYSE: HIMS - Get Free Report) and Schrodinger (NASDAQ: SDGR - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations. Valuation and Earnings This table compares Hims
Amazon could be on the cusp of an artificial intelligence (AI)-driven boom in profitability. Hims & Hers Health stock is pricey, but the company's massive growth potential makes up for it.
HIMS leverages a software-driven platform to scale personalized digital care across new health categories and markets.
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $32.34, indicating a +2.05% shift from the previous trading day.
HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.